380 related articles for article (PubMed ID: 27654928)
1. Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.
Wanchoo R; Abudayyeh A; Doshi M; Edeani A; Glezerman IG; Monga D; Rosner M; Jhaveri KD
Clin J Am Soc Nephrol; 2017 Jan; 12(1):176-189. PubMed ID: 27654928
[TBL] [Abstract][Full Text] [Related]
2. Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
Hobeika L; Self SE; Velez JC
BMC Nephrol; 2014 Sep; 15():156. PubMed ID: 25267524
[TBL] [Abstract][Full Text] [Related]
3. Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma.
Salvini M; Bonello F; Boccadoro M; Larocca A
Expert Rev Anticancer Ther; 2017 Jan; 17(1):75-87. PubMed ID: 27894203
[TBL] [Abstract][Full Text] [Related]
4. Emerging therapies in multiple myeloma.
El-Amm J; Tabbara IA
Am J Clin Oncol; 2015 Jun; 38(3):315-21. PubMed ID: 23934133
[TBL] [Abstract][Full Text] [Related]
5. Treatment-related symptom management in patients with multiple myeloma: a review.
Colson K
Support Care Cancer; 2015 May; 23(5):1431-45. PubMed ID: 25646616
[TBL] [Abstract][Full Text] [Related]
6. Emerging biological insights and novel treatment strategies in multiple myeloma.
Gentile M; Recchia AG; Mazzone C; Morabito F
Expert Opin Emerg Drugs; 2012 Sep; 17(3):407-38. PubMed ID: 22920042
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of multiple myeloma with elotuzumab plus pomalidomide and dexamethasone].
Rasche L; Einsele H; Nitschmann S
Internist (Berl); 2019 Jun; 60(6):658-660. PubMed ID: 30941437
[No Abstract] [Full Text] [Related]
8. Management of double-refractory multiple myeloma.
Meadows JP; Mark TM
Curr Hematol Malig Rep; 2013 Dec; 8(4):253-60. PubMed ID: 23975677
[TBL] [Abstract][Full Text] [Related]
9. Latest advances and current challenges in the treatment of multiple myeloma.
Mahindra A; Laubach J; Raje N; Munshi N; Richardson PG; Anderson K
Nat Rev Clin Oncol; 2012 Feb; 9(3):135-43. PubMed ID: 22349016
[TBL] [Abstract][Full Text] [Related]
10. Novel therapies in monoclonal gammopathies.
Niesvizky R
Hematology; 2012 Apr; 17 Suppl 1():S121-4. PubMed ID: 22507798
[TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibitors for the treatment of multiple myeloma.
Scalzulli E; Grammatico S; Vozella F; Petrucci MT
Expert Opin Pharmacother; 2018 Mar; 19(4):375-386. PubMed ID: 29478351
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review.
Li W; Garcia D; Cornell RF; Gailani D; Laubach J; Maglio ME; Richardson PG; Moslehi J
JAMA Oncol; 2017 Jul; 3(7):980-988. PubMed ID: 27632640
[TBL] [Abstract][Full Text] [Related]
13. Development of target-specific treatments in multiple myeloma.
Chanan-Khan AA; Borrello I; Lee KP; Reece DE
Br J Haematol; 2010 Oct; 151(1):3-15. PubMed ID: 20618339
[TBL] [Abstract][Full Text] [Related]
14. Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.
Pantani L; Brioli A; Tacchetti P; Zannetti BA; Mancuso K; Rocchi S; Martello M; Rizzello I; Terragna C; Zamagni E; Cavo M
Expert Rev Hematol; 2016 Mar; 9(3):315-23. PubMed ID: 26634945
[TBL] [Abstract][Full Text] [Related]
15. Novel therapeutics in multiple myeloma.
Stewart AK
Hematology; 2012 Apr; 17 Suppl 1(0 1):S105-8. PubMed ID: 22507794
[TBL] [Abstract][Full Text] [Related]
16. [New drugs in the treatment of multiple myeloma].
Oriol A; Motlló C
Med Clin (Barc); 2014 Sep; 143(6):268-74. PubMed ID: 24342015
[TBL] [Abstract][Full Text] [Related]
17. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.
Morgan G
Blood Rev; 2010 Nov; 24 Suppl 1():S27-32. PubMed ID: 21126634
[TBL] [Abstract][Full Text] [Related]
18. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O
JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891
[TBL] [Abstract][Full Text] [Related]
19. Carfilzomib: a next-generation proteasome inhibitor for multiple myeloma treatment.
Bilotti E
Clin J Oncol Nurs; 2013 Apr; 17(2):E35-44. PubMed ID: 23538263
[TBL] [Abstract][Full Text] [Related]
20. Future agents and treatment directions in multiple myeloma.
Ocio EM; Mitsiades CS; Orlowski RZ; Anderson KC
Expert Rev Hematol; 2014 Feb; 7(1):127-41. PubMed ID: 24350987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
